Global Neurovascular Devices Market Set To Grow To $3.3bn By 2022

03 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Neurovascular Devices Market Forecast to 2027: Cerebral Embolization and Aneurysm Coiling Devices, Cerebral Angioplasty and Stenting Systems, Support Devices, Neurothrombectomy Devices
The neurovascular devices market is segmented into Cerebral Embolization and Aneurysm Coiling Devices, Cerebral Angioplasty and Stenting Systems, Support Devices, and Neurothrombectomy Devices. The market includes products such as clot retrieval devices, microcatheters, guidewires, stent retrievers, aspiration systems, etc.

The lead analyst of the report commented “The neurovascular devices market is driven by aging population, high incidence of obesity, increasing demand for minimally invasive procedures, and growing awareness of neurovascular diseases. In addition, technological advancements to develop new devices will further drive the market growth. The weaknesses of the market include high cost of devices and disadvantages of neurovascular devices.

However, increasing healthcare expenditures to provide better facilities and automated products showcase growing opportunities for the market growth. High cost of R&D activities and alternative medication therapies pose a major threat to the neurovascular devices market.”

Leading companies featured in the report include Stryker Corporation, Medtronic
Johnson & Johnson, Terumo, Penumbra.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

“Global Ophthalmic Equipment market set to grow to $75bn by 2024” says new Visiongain report

here is a growing demand for ophthalmic equipment such as vision care products and ophthalmology surgical devices, mainly due to the increasing incidence of myopia across the world.

03 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever